Brought to you by 
Endocyte nets $102mm through public offering
10 Jun 2021
Executive Summary
Endocyte Inc. sold 5.2mm common shares (including the overallotment) at $21 apiece in a public offering that netted $102mm. The company is developing small-molecule drug conjugates and companion imaging diagnostics for cancer and other serious diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endocyte nets $102mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice